CYCLERION THERAPEUTICS INC (CYCN) Stock Price, Quote, News and Overview
NASDAQ:CYCN - Nasdaq - US23255M2044 - Common Stock
CYCN Quote and Key Statistics
CYCLERION THERAPEUTICS INC
NASDAQ:CYCN (1/22/2025, 2:32:40 PM)
2.91
+0.01 (+0.34%)
CYCN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.15% | ||
| ROE | -64.2% | ||
| Debt/Equity | 0 |
CYCN Performance and Technical Analysis
CYCN Ownership and Analysts
CYCN Latest News and Analysis
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion is leveraging its legacy sGC stimulator assets to generate near-term revenues which will be used to implement its strategic building plan....
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors of Cyclerion....
About CYCN
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The firm operates through the human therapeutics segment. The firm is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The firm is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Company Info
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Company Website: https://www.cyclerion.com/
Investor Relations: http://ir.cyclerion.com/
Phone: 16176217722
CYCN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.86 | 301.32B | ||
| AMGN | AMGEN INC | 14.28 | 147.50B | ||
| GILD | GILEAD SCIENCES INC | 21.04 | 116.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 843.25 | 110.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.17B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.46B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.67B | ||
| NTRA | NATERA INC | N/A | 22.79B | ||
| BIIB | BIOGEN INC | 8.76 | 20.86B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.54B |